A Phase III, Open-Label, Multicenter Trial to Evaluate Ejection Fraction, End-Diastolic and End-Systolic Volumes, by Unenhanced and DEFINITY-Enhanced 2D-Echo and Magnetic Resonance Imaging
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Perflutren (Primary)
- Indications Cardiovascular disorders
- Focus Diagnostic use; Registrational
- Acronyms BENEFIT1
- Sponsors Lantheus Medical Imaging
- 14 Nov 2019 Status changed from recruiting to completed.
- 20 Feb 2019 Planned End Date changed from 1 Jun 2019 to 1 Sep 2019.
- 20 Feb 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Sep 2019.